サンプル依頼リスト カート
  • English
  • Korean
表紙：世界の産後うつ市場-2023年～2030年
市場調査レポート
商品コード
1352190

世界の産後うつ市場-2023年～2030年

Global Postpartum Depression Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
世界の産後うつ市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

産後うつの世界市場は、有病率の増加、臨床試験の増加など、そのダイナミクスに影響を与える様々な要因によって、近年著しい成長と変貌を遂げています。より良い患者カウンセリングと患者のための治療のために、政府投資は継続的に増加しており、これが世界市場を引き続き牽引し、押し上げるでしょう。世界の産後うつ市場は、新しい治療オプションを通じてその影響を軽減することにますます重点を置いています。

さらに、産後うつ患者は通常、感情の起伏が激しく、頻繁に泣き、疲労、罪悪感、不安を経験し、赤ちゃんの世話に苦労することもあります。産後うつは薬物療法とカウンセリングで治療するのが一般的です。治療法は病気の種類や状態によって異なります。産後うつの治療には、精神療法、抗うつ薬、抗不安薬などが用いられます。精神療法は第一選択の治療法と考えられています。

同様に、北米は産後うつ市場を独占しており、同地域の有利な償還政策、先進医療インフラ、大手企業の存在によって最大の市場シェアを獲得しています。

有病率の増加、認知度の向上、より良い治療、臨床試験の増加、新規治療薬に対する需要の増加、心理療法に対する需要の増加、治療オプションの進歩などの要因によって、予測期間中、世界の産後うつ市場は牽引されると予想されます。

ダイナミクス

研究活動と臨床試験の増加が市場の成長を促進すると予想される

研究活動や臨床試験は継続的に増加しており、予測期間中の市場シェアを牽引すると期待されます。産後うつの分野における研究活動と臨床試験の増加は、治療の安全性と有効性を考慮し、手頃な費用でより良い治療を行うための先進的な治療オプションの開発に役立っています。産後うつ分野の研究活動は、主に薬物の早期吸収に焦点を当てており、早期に症状を軽減するのに役立っています。

例えば、2022年9月26日、革新的な治療法を開発する多国籍企業であるBrii Biosciences Limitedは、産後うつ（PPD）治療薬として開発中の長時間作用型単回注射療法BRII-296を評価する第1相試験のトップライン結果を発表しました。これらのデータは、BRII-296 600mgの筋肉内注射による単回治療が、用量漸増や漸減を必要とすることなく、用量直線性、早期薬物吸収、徐放性および徐放性プロファイルを達成したことを示しており、この用量がPPD治療において臨床効果を達成する可能性があることを確信させるものです。

さらに、産後うつに関する継続的な研究活動により、患者の転帰を改善する治療の機会が拡大し、革新的な治療アプローチの開発により、治療効果を高める光線療法など、新たな治療法の可能性が発見されています。このような進歩により、症状を軽減することで新薬や治療法のイントロダクションへの道が広がります。

例えば、2022年10月13日、ミシガン大学は、産後うつに対するウェアラブルな朝の光治療に関する臨床試験の募集を開始したと発表しました。この研究では、産後うつの女性を対象に、消費者向け健康光治療器（Re-Timer）を試験し、それが気分や体内時計（概日時計とも呼ばれる）にどのように影響するかをより深く理解します。この研究は2025年5月13日に終了する予定です。

革新的な治療薬に対する需要の増加が産後うつ市場の成長を牽引すると期待される

革新的な治療薬に対する需要の高まりが、予測期間中の市場の牽引役となることが期待されます。心理療法やさまざまな抗うつ薬、抗不安薬などの既存の治療法は良好な結果を示しています。しかし、それでもなお、疾患の重症度を特定し、非常に短期間で症状を軽減することによって、より高い効果を発揮する新規抗うつ薬のような革新的な治療薬に対する需要が継続的に増加しています。

例えば、2023年8月4日、バイオジェン社（Biogen Inc.）とセージ・セラピューティクス社（Sage Therapeutics, Inc.）は、米国食品医薬品局（FDA）が産後うつ（PPD）の成人患者を対象にZURZUVAE（ズルズバエ）50mgを承認したと発表しました。ZURZUVAEは、1日1回、14日間の経口投与で、PPDの女性の抑うつ症状を速やかに改善することができる、最初で唯一の治療薬です。ZURZUVAEは、90日以内に予定されている米国麻薬取締局による規制薬物としての指定後まもなく、2023年第4四半期に上市され、市販される予定です。

さらに、産後うつ患者の中には、自分の状態や状況に戸惑う人もいるため、早期発見が症状の重症化を抑えるのに役立つ可能性があります。革新的な検査とAI技術は、早期段階で自宅で病気を特定するのに役立ちます。このような早期発見は、より良い結果を示す新しい治療薬による早期治療に役立ちます。

例えば、2023年4月3日、UVAヘルスとディオニソス・デジタル・ヘルス（Dionysus Digital Health）というデジタルヘルス・スタートアップは、今秋、家庭での血液検査とAIを活用して、産後うつのリスクを予見できるアプリの発売を、今年の第3四半期に上市しようと目指しています。まだ初期段階ですが、同社は最終的に米国FDAにこの検査の認可を申請するつもりです。

知識と認識の不足が市場成長の妨げになる見込み

産後うつとその関連薬に関する知識や認知度の不足が市場の成長を妨げると予想されます。産後うつの認知度は早期発見に役立ち、より良い治療につながる可能性がありますが、この認知度の低さが症状の重症化につながる可能性があります。認知度が低いと産後うつの研究資金が少なくなり、革新的な診断法や治療法の開発が遅れる可能性があります。

産後うつが速やかに認識され、治療されない場合、時間とともに悪化し、症状がより重くなり、回復に要する期間が長くなる可能性があります。このような治療の遅れは、母親と子どもの両方に長期的な影響を及ぼす可能性があります。産後うつの多くは、この疾患に対する認識不足のために診断されなかったり、治療されなかったりします。女性や医療提供者がその症状を認識できず、介入や治療の機会を逃してしまうこともあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 研究活動と臨床試験の増加
      • 革新的な治療薬に対する需要の増加
    • 抑制要因
      • 知識と意識の不足
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ紛争分析
  • DMIの見解

第6章 COVID-19分析

第7章 疾患タイプ別

  • 産後ブルー（赤ちゃんブルー）
  • 産後不安
  • 産後強迫性障害（OCD）
  • 産後パニック障害
  • 産後心的外傷後ストレス障害（PTSD）
  • 産後精神病

第8章 治療法別

  • 抗不安薬または抗うつ薬
  • 精神療法
    • 認知行動療法（CBT）
    • 対人精神療法
  • 電気けいれん療法（ECT）
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 精神科センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Biogen Pharmaceuticals
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Sage Therapeutics
  • Pfizer Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Mallinckrodt Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Sandoz
  • Amneal Pharmaceuticals Pvt. Ltd.
  • Servier Laboratories Ltd.

第13章 付録

目次
Product Code: PH6942

Overview

The global postpartum depression market witnessing significant growth and transformations in recent years, with various factors influencing its dynamics such as increasing prevalence, rising clinical trials, and others. Government investments are continuously rising for better patient counseling and treatment for the patients, this will continue to drive and boost the global market. The global postpartum depression market is placing increasing emphasis to reduce its impact through novel treatment options.

Moreover, patients with postpartum depression usually experience emotional highs and lows, frequent crying, fatigue, guilt, anxiety, and may have trouble caring for their baby. Postpartum depression can be commonly treated with medication and counseling. The treatment is based on the type and state of the disease. Psychotherapy, antidepressants, anti-anxiety medications, and others are used in the treatment of postpartum depression. Psychotherapy is considered a first-line treatment.

Similarly, North America dominates the postpartum depression market, capturing the largest market share owing to the region's favorable reimbursement policies, advanced healthcare infrastructure, and presence of major players.

Owing to the factors such as increasing prevalence, growing awareness and better treatment, rising clinical trials, increasing demand for novel therapeutics, increasing demand for psychotherapy, and advancements in treatment options are expected to drive the global postpartum depression market over the forecast period.

Dynamics

Increasing Research Activities and Clinical Trials are Expected to Drive the Growth of the Market

There are continuously increasing research activities and clinical trials, which are expected to drive market share over the forecast period. The increasing research activities and clinical trials in the field of postpartum depression helps in the development of advanced treatment options for the better treatment by considering the safety and efficacy of the treatment and with affordable costs. The research activities in the field of postpartum depression mainly focus on early drug absorption, which helps to reduce the symptoms early.

For instance, on September 26, 2022, Brii Biosciences Limited, a multi-national company developing innovative therapies, announced top-line results from a Phase 1 study evaluating its long-acting, single-injection therapy, BRII-296, in development for the treatment of postpartum depression (PPD). These data show that a single treatment via intramuscular (IM) injection of 600 mg of BRII-296 achieved dose linearity, early drug absorption, and gradual and extended-release profiles without the need for dose titration or tapering, providing confidence that this dose has the potential to achieve clinical efficacy in the treatment of PPD.

Moreover, the ongoing research activities on postpartum depression enhance the treatment opportunities with better patient outcomes, and the development of innovative treatment approaches has led to the discovery of potentially novel treatment options such as light therapies for enhanced treatment. These advancements increase the way for the introduction of novel drugs and therapies by reducing the symptoms.

For instance, on October 13, 2022, the University of Michigan announced that they started recruiting for clinical trials on a wearable morning light treatment for postpartum depression. This study will test a consumer health light therapy device (Re-Timer) for women with postpartum depression to better understand how it affects mood and the body clock (also called the circadian clock). It is estimated that the study will end on May 13, 2025.

Increasing Demand for Innovative Therapeutics is Expected to Drive the Growth of the Postpartum Depression Market

There increasing demand for innovative therapeutics, which is expected to drive the market over the forecast period. The existing therapies such as psychotherapy and various antidepressants and anti-anxiety medicines show good results. But, still, there is a continuously increasing demand for innovative therapeutics like novel antidepressant drugs with enhanced results by identifying the severity of the disease and reducing the symptoms in a very short period.

For instance, on August 04, 2023, Biogen Inc. and Sage Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD. ZURZUVAE is expected to launch and be commercially available in the fourth quarter of 2023 shortly following scheduling as a controlled substance by the U.S. Drug Enforcement Administration, which is anticipated to occur within 90 days.

Moreover, some patients with postpartum depression may get confused about their condition and situation, so early detection may helps to reduce the severity of the condition. The innovative tests and AI technologies are helps to identify the disease at home in the early stages. This early detection of the condition helps to treat the condition in the early stages with novel therapeutics which shows better results.

For instance, on April 03, 2023, UVA Health and Dionysus Digital Health, a digital health start-up aims to launch an at-home blood test and AI-driven app this fall that could predict the risk of postpartum depression as early as in the third trimester. Still in its early stages, the company eventually intends to file for US FDA clearance of the test.

Lack of Knowledge and Awareness is Expected to Hamper the Market's Growth

The lack of knowledge and awareness about postpartum depression and its associated medications is expected to hamper the growth of the market. The awareness of postpartum depression may helps in the early detection and seeks to better treatment, but this lack of awareness may leads to the severity of the condition. Limited awareness can result in less funding for research into postpartum depression, potentially slowing down the development of innovative diagnostic methods and treatment options.

When postpartum depression is not promptly recognized and treated, it can worsen over time, leading to more severe symptoms and longer recovery periods. This delayed treatment can have long-term implications for both the mother and the child. Many cases of postpartum depression go undiagnosed or untreated due to a lack of awareness about the condition. Women and healthcare providers may not recognize the symptoms, leading to missed opportunities for intervention and treatment.

Segment Analysis

The global postpartum depression market is segmented based on type, treatment, end-user and region.

The Psychotherapy Segment Accounted for Approximately 45.3% of the Postpartum Depression Market Share

The psychotherapy segment is expected to hold the largest market share over the forecast period. Psychotherapy is also known as talk therapy or mental health counseling. The therapy helps to talk through the patient's concerns with a psychiatrist, psychologist, or other mental health professional. Through this therapy, patients can find better ways to cope with their feelings, solve problems, set realistic goals, and respond to situations in a positive way. Sometimes family or relationship therapy also helps. Psychotherapy for postpartum depression includes cognitive-behavioral therapy (CBT) and interpersonal psychotherapy.

Moreover, psychotherapy is a non-invasive treatment option, making it preferable for many women who may be hesitant to take medication during pregnancy or while breastfeeding. It also carries fewer side effects compared to some medications. This therapy can be tailored to the individual's specific needs and circumstances. Therapists work with clients to address their unique experiences and challenges associated with postpartum depression. Many clinical trials and research activities are still going for innovations in psychotherapy or novel psychotherapy.

For instance, on October 29, 2022, the Weill Medical College of Cornell University announced that they are started the clinical trials for a novel social reward psychotherapy for postpartum depression. This study tests a novel psychotherapy, Engage & Connect, tailored to reduce postpartum depression. The study includes 9 weeks of psychotherapy, delivered remotely. It will examine changes in social isolation, processing of social rewards, and depression severity over 9 weeks of treatment. It is estimated that the study will end on July 29, 2027.

Geographical Penetration

North America Accounted for Approximately 39.7% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Well-Established Healthcare Infrastructure

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and well-established healthcare infrastructure. North America especially the United States and Canada is home to many pharmaceutical, research institutes, and medical device companies. The region's strong presence of major players will be forefront in performing clinical trials and research activities which leads to the launch of innovative therapeutics.

For instance, on June 08, 2022, Anthem Inc., the largest for-profit managed healthcare company and a provider of health insurance in the United States, announced that it will offer a digital solution to mothers in order to support maternal mental healthcare needs. The payer partnered with a vendor, Happify Health, to offer a tool that mothers can use to support their recovery from postpartum depression.

Furthermore, North America is also known for its advanced and well-established healthcare infrastructure including hospitals, specialty clinics, psychiatric centers, and others which operates and treats patients with advanced therapies and novel drugs which results in better patient outcomes. The improved insurance coverage offers the better treatment for many patients at affordable costs, leading to market dominance in the region.

Competitive Landscape

The major global players in the postpartum depression market include Biogen Pharmaceuticals, Sage Therapeutics, Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc, Mallinckrodt Pharmaceuticals, Dr. Reddy's Laboratories, Sandoz, Amneal Pharmaceuticals Pvt. Ltd., and Servier Laboratories Ltd. among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global postpartum depression market. During the pandemic, many clinical trials and research activities on postpartum depression have been temporarily disrupted and regulatory approvals have been temporarily postponed due to the redirected focus on the COVID-19 pandemic.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions due to the severity of COVID-19, impacting regular pregnancy and postpartum check-ups, appointments, and consultations worldwide. Many hospitals are focused on the COVID-19 cases, this reduced the focus on the postpartum depression related treatments.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials of postpartum depression therapeutics such as anti-depressants and others. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for treatment due to disruptions in their supply chain networks.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global postpartum depression market owing to the absence of key market players in this region. The impact of the import and export of raw materials is expected to have little influence over the global postpartum depression market growth over the forecast period.

By Type

  • Postpartum Blues (baby blues)
  • Postpartum Anxiety
  • Postpartum Obsessive-Compulsive Disorder (OCD)
  • Postpartum Panic Disorder
  • Postpartum Post-Traumatic Stress Disorder (PTSD)
  • Postpartum Psychosis

By Treatment

  • Anti-Anxiety or Antidepressant Medicines
  • Psychotherapy
    • Cognitive-Behavioral Therapy (CBT)
    • Interpersonal Psychotherapy
  • Electroconvulsive Therapy (ECT)
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Psychiatric Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On December 15 2022, Pranaiya and Arthur Magoffin Foundation (PAM Foundation) is proud to announce a collaboration with the University of Oxford focused on postpartum depression (PPD) and other perinatal mental health illnesses.
  • On June 30 2022, Curio Digital Therapeutics and Axia Women's Health, one of the nation's largest independent women's health groups, are pleased to announce a collaboration agreement to help women at risk for postpartum depression and those diagnosed with postpartum depression. Through the launch of Curio's MamaLift program, patients can access a web-based program that offers personalized self-help tools and trackers to help manage symptoms of anxiety and depression.

DataM Intelligence Opinion:

According to the DataM Intelligence, the postpartum depression market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence and novel therapeutic innovations for better treatment of depression. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects with affordable costs and for effective treatment. Moreover, many clinical trials and research activities are still going, which is expected to growth of the global postpartum depression market in the upcoming years.

Why Purchase the Report?

  • To visualize the global postpartum depression market segmentation based on type, treatment, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of postpartum depression market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global postpartum depression market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Research Activities and Clinical Trials
      • 4.1.1.2. Increasing Demand for Innovative Therapeutics
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Knowledge and Awareness
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine Conflict Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Postpartum Blues (baby blues) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Postpartum Anxiety
  • 7.4. Postpartum Obsessive-Compulsive Disorder (OCD)
  • 7.5. Postpartum Panic Disorder
  • 7.6. Postpartum Post-Traumatic Stress Disorder (PTSD)
  • 7.7. Postpartum Psychosis

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Anti-Anxiety or Antidepressant Medicines *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Psychotherapy
    • 8.3.1. Cognitive-Behavioral Therapy (CBT)
    • 8.3.2. Interpersonal Psychotherapy
  • 8.4. Electroconvulsive Therapy (ECT)
  • 8.5. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Psychiatric Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Biogen Pharmaceuticals *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Sage Therapeutics
  • 12.3. Pfizer Inc.
  • 12.4. Eli Lilly and Company
  • 12.5. GlaxoSmithKline Plc
  • 12.6. Mallinckrodt Pharmaceuticals
  • 12.7. Dr. Reddy's Laboratories
  • 12.8. Sandoz
  • 12.9. Amneal Pharmaceuticals Pvt. Ltd.
  • 12.10. Servier Laboratories Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us